Overview

Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)

Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of intravitreous ranibizumab treatment versus sham injections for prevention of high-risk DR.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators:
Eye & ENT Hospital of Fudan University
RenJi Hospital
Shanghai 10th People's Hospital
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai Tongji Hospital, Tongji University School of Medicine
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Treatments:
Bevacizumab
Ranibizumab